
Kyverna Therapeutics, Inc. – NASDAQ:KYTX
Kyverna Therapeutics stock price today
Kyverna Therapeutics stock price monthly change
Kyverna Therapeutics stock price quarterly change
Kyverna Therapeutics key metrics
Market Cap | 167.07M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeKyverna Therapeutics stock price history
Kyverna Therapeutics stock forecast
Kyverna Therapeutics financial statements
2023 | 0 | -60.36M |
---|
2024-03-26 | -3.23 | -26.86 |
---|---|---|
2024-05-14 | -0.88 | -1.12 |
2023 | 75195000 | 26.01M | 34.6% |
---|
2022 | -36.11M | -14.09M | 11.88M |
---|---|---|---|
2023 | -52.41M | -8.78M | 58.11M |
Kyverna Therapeutics alternative data
Apr 2024 | 96 |
---|---|
May 2024 | 96 |
Jun 2024 | 96 |
Jul 2024 | 100 |
Dec 2024 | 96 |
Kyverna Therapeutics other data
Period | Buy | Sel |
---|---|---|
Feb 2024 | 910000 | 0 |
-
What's the price of Kyverna Therapeutics stock today?
One share of Kyverna Therapeutics stock can currently be purchased for approximately $3.3.
-
When is Kyverna Therapeutics's next earnings date?
Unfortunately, Kyverna Therapeutics's (KYTX) next earnings date is currently unknown.
-
Does Kyverna Therapeutics pay dividends?
No, Kyverna Therapeutics does not pay dividends.
-
How much money does Kyverna Therapeutics make?
Kyverna Therapeutics has a market capitalization of 167.07M. Kyverna Therapeutics made a loss 60.37M US dollars in net income (profit) last year or -$1.12 on an earnings per share basis.
-
What is Kyverna Therapeutics's stock symbol?
Kyverna Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "KYTX".
-
What is Kyverna Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Kyverna Therapeutics?
Shares of Kyverna Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Kyverna Therapeutics have?
As Dec 2024, Kyverna Therapeutics employs 96 workers, which is 4% less then previous month.
-
When Kyverna Therapeutics went public?
Kyverna Therapeutics, Inc. is publicly traded company for just a year since IPO on 9 Feb 2024.
-
What is Kyverna Therapeutics's official website?
The official website for Kyverna Therapeutics is kyvernatx.com.
-
Where are Kyverna Therapeutics's headquarters?
Kyverna Therapeutics is headquartered at 5980 Horton Street, Emeryville, CA.
-
How can i contact Kyverna Therapeutics?
Kyverna Therapeutics's mailing address is 5980 Horton Street, Emeryville, CA and company can be reached via phone at +51 09252492.
Kyverna Therapeutics company profile:

Kyverna Therapeutics, Inc.
kyvernatx.comNASDAQ
96
Biotechnology
Healthcare
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Emeryville, CA 94608
CIK: 0001994702
ISIN: US5019761049
: